Browse

Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects

Cited 81 time in Web of Science Cited 88 time in Scopus
Authors
Weerts, Elise M; Kim, Yu Kyeong; Wand, Gary S; Dannals, Robert F; Lee, Jae Sung; Frost, J James; McCaul, Mary E
Issue Date
2007-05-10
Publisher
Nature Publishing Group
Citation
Neuropsychopharmacology 33(3): 653-665
Keywords
AdultAlcoholism/*drug therapy/*radionuclide imagingAnalgesics, Opioid/diagnostic useData Interpretation, StatisticalFemaleFentanyl/analogs & derivatives/diagnostic useHumansMaleMiddle AgedNaltrexone/blood/pharmacokinetics/*therapeutic useNarcotic Antagonists/blood/pharmacokinetics/*therapeutic usePositron-Emission TomographyRadiopharmaceuticals/diagnostic useReceptors, Opioid, delta/*antagonists & inhibitorsReceptors, Opioid, mu/*antagonists & inhibitorsSubstance Withdrawal Syndrome/psychology/radionuclide imagingTemperance
Abstract
Blockade of brain mu-opioid receptor (mu-OR) and delta-opioid receptor (delta-OR) was investigated in recently abstinent alcohol-dependent subjects (N=21) maintained on naltrexone. Subjects completed a 19-day inpatient protocol, which included alcohol abstinence followed by naltrexone treatment (50 mg) on days 15-19. Blood samples were collected after the first administration of naltrexone to evaluate serum levels of naltrexone and 6-beta-naltrexol. Regional brain mu-OR binding potential (BP) and delta-OR Ki was measured using [11C]carfentanil (CAR) positron emission tomography (PET) and [11C]methyl naltrindole ([11C]MeNTI) PET, respectively, before (day 5) and during naltrexone treatment (day 18). Naltrexone inhibition of [11C]CAR BP was near maximal across all brain regions of interest with little variability across subjects (mean+SD% inhibition=94.9+4.9%). Naltrexone only partially inhibited the [11C]MeNTI Ki and there was more variability across subjects (mean+SD% inhibition=21.1+14.49%). Peak serum levels of naltrexone were positively correlated with % inhibition of delta-OR Ki in neocortex and basal ganglia. Peak serum levels of naltrexone were not correlated with % inhibition of mu-OR BP. Peak levels of 6-beta-naltrexol were not significantly correlated with % inhibition of mu-OR BP or delta-OR Ki. Thus, the FDA recommended therapeutic dose of naltrexone was sufficient to produce near complete inhibition of the mu-OR in recently abstinent alcohol dependent subjects. The lower percent inhibition of delta-OR and greater variability in delta-OR blockade by naltrexone across subjects may contribute to individual differences in treatment outcomes to naltrexone. Further investigations on the relationship between individual differences in delta-OR blockade by naltrexone and clinical outcomes should be explored.
ISSN
0893-133X (Print)
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17487229

http://www.nature.com/npp/journal/v33/n3/pdf/1301440a.pdf

http://hdl.handle.net/10371/67724
DOI
https://doi.org/10.1038/sj.npp.1301440
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Nuclear Medicine (핵의학전공)Journal Papers (저널논문_핵의학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse